1374P Docetaxel/nindetanib as efficient treatment option after failure of immune checkpoint inhibition: Real-world evidence

Autor:	Daniel C. Christoph, S. Winke, I.T. Azeh, K-O. Kambartel, Amin T. Turki, Martin Metzenmacher, Matthias Scheffler, F. Rizzo, Diana S.Y. Abdulla, Jens Panse, Mathias Hoiczyk
Rok vydání:	2020
Předmět:	Oncology medicine.medical_specialty Docetaxel business.industry Internal medicine medicine Treatment options Hematology business Real world evidence Immune checkpoint medicine.drug
Zdroj:	Annals of Oncology. 31:S876
ISSN:	0923-7534
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::181174fb5948cea32603e25fbfef902f https://doi.org/10.1016/j.annonc.2020.08.1688 Zobrazit plný text záznamu